phase ii pathway: adjuvant pembrolizumab in patients with hnsc cancer at high risk for recurrence
Published 3 months ago • 112 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:36
results from keynote-716: adjuvant therapy with pembrolizumab in high-risk stage ii melanoma
-
5:54
keynote-716: adjuvant therapy with pembrolizumab for patients with high-risk stage ii melanoma
-
0:43
keynote-716: adjuvant pembrolizumab for high-risk melanoma
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
1:30
adjuvant therapy for high-risk melanoma
-
1:08
keynote-716: safety profile and results of pembrolizumab for melanoma
-
4:03
keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
-
9:40
reducing recurrence of advanced melanoma with pembrolizumab
-
1:33
ambassador: extended dfs follow-up of adjuvant pembrolizumab in miuc
-
0:41
#adjuvant #pembrolizumab for #rcc #kidneycancer #cancertreatment #cancer
-
2:59
ambassador: adjuvant pembrolizumab in muscle-invasive urothelial carcinoma
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
2:18
keynote-716: longer follow up supports pembrolizumab use in stage iib/iic melanoma
-
0:43
what's on the horizon for adjuvant therapies for rcc?
-
1:00
adjuvant pembrolizumab in kidney cancer from keynote 564
-
1:08
clinical trials in adjuvant rcc
-
1:03
potential of adjuvant therapy for rcc
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer